Alaunos Therapeutics
TCRT
28 hedge funds and large institutions have $345K invested in Alaunos Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 4 closing their positions.
233% more capital invested
Capital invested by funds: $103K → $345K (+$241K)
0.09% less ownership
Funds ownership: 4.42% → 4.33% (-0.09%)
3% less funds holding
Funds holding: 29 → 28 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPIA
Steward Partners Investment Advisory
New York
|
+$3.01K |
| 2 |
Morgan Stanley
New York
|
+$2.71K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.01K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
+$298 |
| 5 |
KFI
Key Financial Inc
West Chester,
Pennsylvania
|
+$72 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$3.17K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.12K |
| 3 |
Barclays
London,
United Kingdom
|
-$214 |
| 4 |
Wells Fargo
San Francisco,
California
|
-$99 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$75 |
TCRT Hedge Fund Activity: Q2 2025 in Review
28 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2025, worth a combined $345K — up 233% from $103K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TCRT and 3 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 3 added.
The largest buyer was Steward Partners Investment Advisory, adding an estimated $3.01K. The largest seller was UBS Group, cutting an estimated $3.17K.
- 28 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2025, down from 29 in Q1 2025.
- Funds reported $345K of Alaunos Therapeutics stock for Q2 2025, up 233% quarter-over-quarter.
- 3 funds opened new Alaunos Therapeutics positions in Q2 2025 and 4 closed out, a net change of -1 holder.
- The largest Alaunos Therapeutics buyer in Q2 2025 was Steward Partners Investment Advisory, an estimated $3.01K added.
- The largest Alaunos Therapeutics seller in Q2 2025 was UBS Group, an estimated $3.17K sold.
Based on aggregated 13F filings for Q2 2025.